Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: A comparison of myeloablative and nonmyeloablative conditioning regimens

Bone Marrow Transplantation

Volumn 41, Issue 10, 2008, Pages 887-893

  Sala Torra, O ^a   Martin, P J ^a,b   Storer, B ^a   Traina, F ^c   Sorror, M L ^a   Storb, R ^a,b   Sandmaier, B M ^a,b   Flowers, M E D ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PSORALEN; RAPAMYCIN; TACROLIMUS; THALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLAST CELL CRISIS; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA TYPING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOTOTHERAPY; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PUVA; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 44449103854     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705987     Document Type: Article

References (43)

1. Flowers MED, Traina F, Storer B, Maris M, Bethge WA, Carpenter P et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning [erratum appears in BMT 2005;35:535). Bone Marrow Transplant 2005; 35: 277-282.
2. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060.
3. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
4. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
5. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
6. Burroughs L, Mielcarek M, Leisenring W, Sandmaier BM, Maloney DG, Baron F et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006: 81: 818-825.
7. Bethge WA, Stover BE, Maris MB, Flowers MED, Maloney DG, Chauncey TR et al. Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: Effect of interventions on outcome. Exp Hematol 2003; 31: 974-980.
8. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
9. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G. Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
10. Sullivan KM. Graft-vs-host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing Ltd: Oxford, UK, 2004, pp. 635-664.
11. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
12. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
13. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
14. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
15. Flowers MED. Emerging strategies in the treatment of chronic graft-versus-host disease: Traditional treatment of chronic graft-versus-host disease (Symposium Report). Blood Marrow Transplant Rev 2002; 12: 5-8.
16. Koc S, Leisenring W, Flowers MED, Anasetti C, Deeg HJ, Nash RA et al Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100: 48-51.
17. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65.
18. Mookerjee B. Altomonte V. Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517-520.
19. Nash RA, Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ et al Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): Safety analysis. Blood 1997; 90 (Suppl. 1): 105a, #459 (abstr.).
20. Carnevale-Schianca. F, Martin P, Sullivan K, Flowers M, Gooley T, Anasetti C et al. Changing cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 613-620.
21. Couriel DR. Saliba R. Escalon MP. Hsu Y, Ghosh S. Ippoliti C et al Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409-417.
22. Flowers MED, Martin PJ. Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease. Leuk Lymphoma 2003: 44: 1141-1146.
23. Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morison WL, Corio R et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 1061-1067.
24. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074-3080.
25. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P et al. Successful use of extra-corporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098-3104.
26. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006; 12: 375-396.
27. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Morb Mortal Wkly Rep 2000; 49: 1-125.
28. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-4071.
29. Marr KA, Seidel K, Slavin M, Bowden RA, Schoch HG, Flowers MED et al Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
30. Conover WJ. Practical Non-parametric Statistics. John Wiley and Sons: New York, 1980.
31. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al Hematopoietic cell transplantation (HCT)- specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
32. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
33. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300 1068-1073.
34. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, The Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529-1533.
35. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
36. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
37. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005; 46: 1251-1260.
38. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
39. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplant comorbidities. Blood 2004; 104: 961-968.
40. Sorror M, Gooley T, Nash R, Petersdorf E, Martin P, Deeg HJ et al. Risk factors associated with increased grades III-IV acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 2006; 12 (Suppl. 1): 55, #153. (abstr.).
41. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004: 10: 178-185.
42. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
43. Sorror M, Maris M, Diaconescu R, Storb R. Lessened severe graft-versus-host after minitransplantations' (Letter to the Editor). Blood 2005: 105: 2614.